KURN - Kuros Biosciences AG - Stock & Dividends
Exchange: SIX Swiss Exchange • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0325814116
Bone Grafts, Pharmaceuticals, Medical Devices
Kuros Biosciences AG is a biopharmaceutical company that focuses on developing and commercializing innovative solutions for tissue repair and bone regeneration globally.
The company operates through three distinct segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio, each playing a crucial role in its overall mission.
In the Medical Devices segment, Kuros Biosciences offers a range of advanced bone graft products, including MagnetOs Granules, which utilizes submicron needle-shaped NeedleGrip surface technology to promote bone growth. Additionally, the company provides MagnetOs Putty, a moldable solution for filling bony voids, and MagnetOs Easypack Putty, a ready-to-use mold for implantation in intervertebral disc spaces or posterolateral spine levels. Furthermore, Magnetos Flex Matrix is an open matrix bone graft designed for optimal bone regeneration.
In the Pharmaceuticals segment, Kuros Biosciences is developing a pipeline of Fibrin-PTH products, including KUR-111 and KUR-113, which are currently in Phase 2b clinical trials for trauma indications. KUR-113 is also being evaluated in a Phase 2a clinical trial for spinal indications, demonstrating the company's commitment to addressing a range of unmet medical needs.
Founded in 2016, Kuros Biosciences is headquartered in Schlieren, Switzerland, and is dedicated to improving patient outcomes through its innovative tissue repair and bone regeneration solutions. For more information, visit the company's website at https://www.kuros.ch.
Drawdown (Underwater) Chart
![Drawdown / Underwater Chart for KURN - Kuros Biosciences AG - Stock & Dividends](https://www.valueray.com/images/drawdown_chart/KURN.SW_drawdown.png)
KURN Stock Overview
Market Cap in USD | 690m |
Sector | Healthcare |
Industry | Medical Devices |
GiC SubIndustry | Health Care Equipment |
TER | 0.00% |
IPO / Inception |
KURN Stock Ratings
Growth 5y | 68.1 |
Fundamental | -40.2 |
Dividend | 0.00 |
Rel. Performance vs Sector | 10.96 |
Analysts | - |
Fair Price Momentum | 37.74 CHF |
Fair Price DCF | - |
KURN Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
KURN Growth Ratios
Growth 12m | 760.51% |
Growth Correlation 12m | 98% |
Growth Correlation 3m | 76% |
CAGR 5y | 66.01% |
CAGR/Mean DD 5y | 2.07 |
Sharpe Ratio 12m | 9.37 |
Alpha vs SP500 12m | 745.58 |
Beta vs SP500 5y weekly | 0.55 |
ValueRay RSI | 88.23 |
Volatility GJR Garch 1y | 71.77% |
Price / SMA 50 | 25.04% |
Price / SMA 200 | 108.19% |
Current Volume | 137.7k |
Average Volume 20d | 277.3k |
External Links for KURN Stock
As of September 08, 2024, the stock is trading at CHF 16.78 with a total of 137,650 shares traded.
Over the past week, the price has changed by +8.54%, over one month by +41.72%, over three months by +83.99% and over the past year by +718.54%.
According to ValueRays Forecast Model, KURN Kuros Biosciences AG will be worth about 41.5 in September 2025. The stock is currently trading at 16.78. This means that the stock has a potential upside of +147.14%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 20.1 | 19.5 |
Analysts Target Price | - | - |
ValueRay Target Price | 41.5 | 147 |